PCSK9 inhibitors. Recommendations for patient selection

被引：1
作者：
Laufs, U. [1 ]
Custodis, F. [1 ]
Werner, C. [1 ]
机构：
[1] Univ Klinikum Saarlandes, Klin Innere Med Kardiol Angiol & Internist Intens, IMED Geb 41-1, D-66421 Homburg, Germany
来源：
HERZ | 2016年 / 41卷 / 04期
关键词：
Proprotein convertase subtilisin-kexin type 9; Safety; Cholesterol; Risk; Review; CORONARY-HEART-DISEASE; SUBTILISIN/KEXIN TYPE 9; DENSITY-LIPOPROTEIN CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; MONOCLONAL-ANTIBODY; STATIN THERAPY; CARDIOVASCULAR EVENTS; LDL-CHOLESTEROL; REDUCING LIPIDS; AMG; 145;
D O I：
10.1007/s00059-016-4429-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The 2 or 4aEuroweek subcutaneous therapy with the recently approved antibodies alirocumab and evolocumab for inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) reduces low-density lipoprotein cholesterol (LDL-C) in addition to statins and ezetimibe by 50-60 %. The therapy is well-tolerated. The safety profile in the published studies is comparable to placebo. Outcome data and information on long-term safety and the influence on cardiovascular events are not yet available but the results of several large trials are expected in 2016-2018. At present (spring 2016) PCSK9 inhibitors represent an option for selected patients with a high cardiovascular risk and high LDL-C despite treatment with the maximum tolerated oral lipid-lowering therapy. This group includes selected patients with familial hypercholesterolemia and high-risk individuals with statin-associated muscle symptoms (SAMS).
引用
收藏
页码：296 / 306
页数：11
相关论文
共 43 条
  • [1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    [J]. NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [2] Familial Hypercholesterolemia and Atherosclerosis in Cloned Minipigs Created by DNA Transposition of a Human PCSK9 Gain-of-Function Mutant
    Al-Mashhadi, Rozh H.
    Sorensen, Charlotte B.
    Kragh, Peter M.
    Christoffersen, Christina
    Mortensen, Martin B.
    Tolbod, Lars P.
    Thim, Troels
    Du, Yutao
    Li, Juan
    Liu, Ying
    Moldt, Brian
    Schmidt, Mette
    Vajta, Gabor
    Larsen, Torben
    Purup, Stig
    Bolund, Lars
    Nielsen, Lars B.
    Callesen, Henrik
    Falk, Erling
    Mikkelsen, Jacob Giehm
    Bentzon, Jacob F.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (166)
  • [3] NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
    Benjannet, S
    Rhainds, D
    Essalmani, R
    Mayne, J
    Wickham, L
    Jin, WJ
    Asselin, MC
    Hamelin, J
    Varret, M
    Allard, D
    Trillard, M
    Abifadel, M
    Tebon, A
    Attie, AD
    Rader, DJ
    Boileau, C
    Brissette, L
    Chrétien, M
    Prat, A
    Seidah, NG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) : 48865 - 48875
  • [4] Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
    Berge, KE
    Ose, L
    Leren, TP
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) : 1094 - 1100
  • [5] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    Cannon, Christopher P.
    Blazing, Michael A.
    Giugliano, Robert P.
    McCagg, Amy
    White, Jennifer A.
    Theroux, Pierre
    Darius, Harald
    Lewis, Basil S.
    Ophuis, Ton Oude
    Jukema, J. Wouter
    De Ferrari, Gaetano M.
    Ruzyllo, Witold
    De Lucca, Paul
    Im, KyungAh
    Bohula, Erin A.
    Reist, Craig
    Wiviott, Stephen D.
    Tershakovec, Andrew M.
    Musliner, Thomas A.
    Braunwald, Eugene
    Califf, Robert M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) : 2387 - 2397
  • [6] Design and Rationale of the GAUSS-2 Study Trial: A Double-Blind, Ezetimibe-Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab ( AMG145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy
    Cho, Leslie
    Rocco, Michael
    Colquhoun, David
    Sullivan, David
    Rosenson, Robert S.
    Dent, Ricardo
    Xue, Allen
    Scott, Rob
    Wasserman, Scott M.
    Stroes, Erik
    [J]. CLINICAL CARDIOLOGY, 2014, 37 (03) : 131 - 139
  • [7] Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    Cohen, JC
    Boerwinkle, E
    Mosley, TH
    Hobbs, HH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) : 1264 - 1272
  • [8] LDL-Cholesterol: From the Hypothesis to Causality
    Custodis, Florian
    Laufs, Ulrich
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (10) : 761 - U71
  • [9] Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
    Denis, Maxime
    Marcinkiewicz, Jadwiga
    Zaid, Ahmed
    Gauthier, Dany
    Poirier, Steve
    Lazure, Claude
    Seidah, Nabil G.
    Prat, Annik
    [J]. CIRCULATION, 2012, 125 (07) : 894 - U173
  • [10] DIETSCHY JM, 1993, J LIPID RES, V34, P1637
12345